Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip™ Passes Animal Study Jul 1, 2024 05:30AM
Anteris Provides Update on DurAVR™ THV Valve-in-Valve Experience Presented at New York Valves 2024 Jun 13, 2024 06:00AM
Anteris Provides Data Update on First in Human Study of DurAVR™ THV Presented at New York Valves 2024 Jun 11, 2024 06:00AM
Anteris Announces Participation at the Cantor Healthcare Conference on Sept 26th 2023 Sep 12, 2023 04:30PM
DurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve Case Aug 14, 2023 06:00AM


Aug 9, 2023 06:30AM Anteris Technologies Commences American Depository Receipt Program
Aug 9, 2023 06:00AM Anteris Technologies Commences US Early Feasibility Study
Jul 31, 2023 06:00AM Anteris Technologies Announces First Successful Implantation of DurAVR™ THV in a Valve-in-Valve Procedure
Feb 15, 2023 08:00AM Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Nov 28, 2022 08:00AM Anteris Technologies Receives FDA Clearance to Initiate Early Feasibility Study for its Novel TAVR Product, DurAVR™
Sep 13, 2022 05:30AM Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston
Sep 13, 2022 05:30AM Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston